开楼关注德国HEB

sinnlos

231# 如风

准备赚多少抛啊？够买新车？
我买了1千股

moon2966

http://www.stockmarketcats.com/f ... harma-inc-4538.html



Hemispherx Biopharma, Inc. (NYSE Alternext US:HEB) has scheduled a conference call and audio webcast to discuss its year-end 2008 results and the new clinical data recently presented at the 9th International IACFS/ME conference held in Reno, NV from March 12 - 15, 2009. The conference call and webcast are scheduled for Thursday, March 19, 2009 at 10:00 AM EDT.

At the 9th International IACFS/ME conference, Dr. David Strayer, Hemispherx's Medical Director, presented new, never before released cytokine data and cardiovascular data which has been included in the New Drug Application (NDA) filed with the Food and Drug Administration (FDA) with a current PDFUDA date of May 25, 2009. Dr. William Carter, Hemispherx's Chairman and CEO, will discuss the data and its significance on the conference call. The presentation given by Dr. Strayer at the conference is available for review one hour prior to this conference call on the company's website at www.hemispherx.net.

To access the conference call: U.S. Callers: 800-346-7359 International Callers: 973-528-0008 Conference Entry Code: 520147

This call will be webcast via the Company's website at: http://www.hemispherx.net.

A digital replay of the call will be available until April 2, 2009 by calling: U.S. Callers: 800-332-6854 International Callers: 973-528-0005 Conference Entry Code: 520147

moon2966

http://www.pr-inside.com/special ... issued-r1262296.htm

http://biomedreports.com/article ... g-fda-decision.html

xxtrader

别担心，我是 1.23 进的。
老亥 发表于 2009-5-22 17:53

别担心俺1.30进得

buddha

现在都没钱了. 等着看看.

hansen73

别担心俺1.30进得
xxtrader 发表于 2009-5-22 22:57

你们说的是美金还是欧元啊？？

如风

231# 如风

准备赚多少抛啊？够买新车？
我买了1千股
sinnlos 发表于 2009-5-22 18:44

如果通过了，我想还不长到10块，2w欧也够买一辆新的啦

moon2966

俺昨天晚上做完功课，就安心睡觉了。

. The presentation given by Dr. Strayer at the conference is available for review one hour prior to this conference call on the company's website at www.hemispherx.net.

还没发表报告。说明这老兄，周二才报告 俺小脑袋推理出来的

老亥

你们说的是美金还是欧元啊？？
hansen73 发表于 2009-5-23 01:44

我是欧元啊！

一个老人，

handada

俺昨天晚上做完功课，就安心睡觉了。

. The presentation given by Dr. Strayer at the conference is available for review one hour prior to this conference call on the company's website at ...
moon2966 发表于 2009-5-23 06:55

做完功课 ?    甚么功 ?  好用功啊。

moon2966

抗议老亥，总说自己老。

俺作HEB的功课啊。看看能不能找到报告。

老亥

抗议老亥，总说自己老。

俺作HEB的功课啊。看看能不能找到报告。
moon2966 发表于 2009-5-23 07:27

抗议无效，谁还比我老？上次教会聚会烧烤，我再老年组打排球，我在老年组里，算是中年人！

明年就快60了！

moon2966

还没到法定退休年龄呢。到了还算是年轻的老年人。只看年轻^%人这几个字，还属于年轻人呢。
等几十年，俺也升级成p6

moon2966

又翻到两个评论。等周二检验了

bengbeng发表于 2009-5-8 00:26  | 只看该作者
Hemispherx Biopharma, Inc., a biopharmaceutical company, engages in the clinical development, manufacture, marketing, and distribution of drugs for the treatment of viral and immune-based chronic disorders. The company’s products include Ampligen, an experimental drug that is in clinical development for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, HIV, renal cell carcinoma, and malignant melanoma; and Alferon N Injection, a clinical development stage product for treating Multiple Sclerosis, West Nile Virus, and SARS, as well as for the treatment of genital warts. It is also developing Alferon LDO, an experimental low-dose, oral liquid formulation of natural alpha interferon, which is used for the treatment for viral diseases. In addition, through a licensing agreement with Temple University in Philadelphia, Pennsylvania, the company offers Oragens, a set of oral broad spectrum antivirals and immunological enhancers for the treatment of chronic viral and immunological disorders. Hemispherx Biopharma, Inc. was founded in 1990 and is headquartered in Philadelphia, Pennsylvania.

Flu题材， 日本看好，动物实验成功，不知到人体还多久

http://finance.yahoo.com/news/Ja ... nt-pz-15041028.html

4月9号file SEC，申请要增发21个million common stock融资

http://secfilings.nasdaq.com/fil ... 2F9%2F2009&pdf=

他们自己定的计划是

----------------------------------------------------------------------------------------------------------------
    Assumed Average     Number of Remaining        Percentage of Outstanding   Proceeds from the Sale of
                                                   Shares After Giving Effect  Shares to Fusion Capital Listed
                        Shares to be Issued if     to the Issuance of Such     the Second Column Under the
    Purchase Price      Full Purchase              Shares to Fusion Capital(1) Purchase Agreement
----------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------
$0.40                   15,622,485                 16.0%                       $ 6,248,994
----------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------
$0.48 (2)               15,622,485                 16.0%                       $  7,498,793
----------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------
$0.75                   15,622,485                 16.0%                       $ 11,716,864
----------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------
$1.00                   15,622,485                 16.0%                       $ 15,622,485
----------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------
$1.50                   15,622,485                 16.0%                       $ 23,433,728
----------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------
$2.00                   14,070,000                 14.4%                       $ 28,140,000
----------------------------------------------------------------------------------------------------------------

我是不买了，我觉得看不出什么好来，作价销售股票而以。如果要买，你们跟吧，路线图都给写在这里了

moon2966

bengbeng发表于 2009-5-8 01:55  | 只看该作者
已经有的药，
Alferon N Injection(R) 是检测女性性病genital warts复发的
http://treatmentforgenitalherpes ... -and-genital-herpes
同时实验是不是能对West Nile Virus有效

另外一种是治疗Chronic Fatigue Syndrome，谁知道中文是什么？（神经官能症？疲劳综合症？）
http://www.learningdiscoveries.org/ChronicFatigueSyndrome.htm

Ampligen(R)
In August 2004, we completed a Phase III clinical trial ("AMP 516") treating over 230 CFS patients with Ampligen(R) and are presently in the registration process for a new drug application ("NDA") with the Food and Drug Administration ("FDA"). Over its developmental history, Ampligen(R) has received various designations, including Orphan Drug Product Designation (FDA), Emergency (compassionate) Cost Recovery Sales Authorization (FDA) and "promising" clinical outcome recognition based on the evaluation of certain summary clinical reports (AHRQ, Agency Health Research Quality). Ampligen represents the first drug in the class of RNA (nucleic acid) molecules to apply for NDA review.

On July 7, 2008, the FDA accepted for review our NDA for Ampligen(R) to treat CFS, originally submitted in October 2007. We are seeking marketing approval for the first-ever treatment for CFS. At present, only supportive, symptom-based care is available for CFS patients. The NDA for Ampligen(R), whose chemical designation is poly I : poly C12U, is also the first ever accepted for review by the FDA for systemic use of a toll-like receptor therapy to treat any condition. On February 18, 2009, we were notified by the FDA that the originally scheduled Prescription Drug User Fee Act ("PDUFA") date of February 25, 2009 has been extended to May 25, 2009.

5月25是大限，批了就是新药，不批也完成了融资

药的世界真是太有意思了！

可笑的就是这个公司，自1966年以来积累了197M dollar的损失，最后剩下6M，已有的药也停了，生产线正在接受FDA新药审查，已有的要库存都过期了，没办法销售，现在委托一个公司0.4以上发行新股21M，整个outstanding稀释到100M shares，我横竖觉得这个公司很不得法，不是个什么有气量的公司，什么都做，小里小气的，难成大气候！研究的也都是说不清道不明的东西，值钱吗？

最近的变化是日本公司觉得这个新药可以结合它们的东东一起治疗还是预防H5N1，H1N1, H3N2，目前在非独家使用，进行二期实验。

如果成功，市场多大呢？

As reported in the Journal of American Medical Association in 2003 by Thompson, Shay, Weintraub, Brammer, Cox, Anderson, et al. seasonal influenza kills approximately 36,000 Americans annually, most over the age of 70. In 2004 in JAMA, the same authors attributed 200,000 U.S. hospital admissions annually to seasonal flu.

可不全是用这家的药哦！我的感觉，这家公司志向远大，商业行为不着边际

看看这群老人

Name                  Age      Position

William A. Carter, M.D.         71       Chairman, Chief Executive Officer

Charles T. Bernhardt, CPA       47       Chief Financial Officer

David R. Strayer, M.D.          63       Medical Director, Regulatory Affairs

Carol A. Smith, Ph.D.           57       VP of Manufacturing Quality and Process
                                         Development

Richard C. Piani                80       Director

Thomas K. Equels                58       Director

Katalin Ferencz-Biro            62       Senior Vice President of Regulatory
                                         Affairs

William M. Mitchell, M.D.       74       Director

Ransom W. Etheridge             69       Secretary and General Counsel

Iraj Eqhbal Kiani, Ph.D.        61       Director

Wayne Springate                 38       Vice President of Operations

Russel Lander                   58       Vice President of Quality Assurance

唉，没戏，即使飞起来一会儿也没戏！我判了死刑了，你们还是可以短期做，人家融资计划都写好了，在上面一帖

如风

看他们这次利用机会两次增发很显然自己也没有信心，可能只是利用机会卖股票了

moon2966

功课没做好。内疚一下。

moon2966

看他们这次利用机会两次增发很显然自己也没有信心，可能只是利用机会卖股票了
如风 发表于 2009-5-23 08:09

过不过，对公司来说，这次运作都很成功。money有了，可以继续搞下去。

股票至少没有被清盘的危险。
过了，看评论的目标是5。5$

moon2966

今天又看了下分析。周五某A庄利用某B庄stop loss 清了他1百多万手，恰当的是抢劫了1百多万手。
其他是散户跟抛。预计周二下班后才公布。周二开盘还要互相倾轧一下。可能还会低。
当然某牛人从两次发股分析要过。

俺看到什么，先做着笔记。等回头一起验证一下。

本青蛙，没脑子，目前还属于跟风状态。

如风

今天又看了下分析。周五某A庄利用某B庄stop loss 清了他1百多万手，恰当的是抢劫了1百多万手。
其他是散户跟抛。预计周二下班后才公布。周二开盘还要互相倾轧一下。可能还会低。
当然某牛人从两次发股分析要过。
...
moon2966 发表于 2009-5-24 10:19

请问哪个牛人分析要过啊